2022
Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients
Ramchandren S, Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Mantecon M, Ling L, Zhu Y, Karcher K, Sun H. Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology 2022, 99: s35-s37. DOI: 10.1212/01.wnl.0000903304.73134.e3.Peer-Reviewed Original ResearchPhase 2 studyMyasthenia gravis patientsClinical improvementGravis patientsMonoclonal antibodiesAnti-AChR autoantibodiesMuSK-positive patientsMyasthenia Gravis ActivitiesDaily living scoreSerum total IgGSerum IgG levelsMG-ADL scoreNeonatal Fc receptorGMG patientsClinical responseDose armLiving scorePathogenic autoantibodiesPositive patientsIgG levelsPathogenic antibodiesIgG autoantibodiesPharmacodynamic effectsSerum IgGTotal IgG
2020
Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study
Litchman T, Roy B, Kumar A, Sharma A, Njike V, Nowak RJ. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. Journal Of The Neurological Sciences 2020, 411: 116690. PMID: 32028072, DOI: 10.1016/j.jns.2020.116690.Peer-Reviewed Original ResearchConceptsMyasthenia gravisMGFA classRetrospective studyPositive myasthenia gravis patientsSingle-center retrospective studyManagement of MGAcetylcholine receptor autoantibodiesRefractory myasthenia gravisSymptom-free stateB-cell depletionMyasthenia gravis patientsClinical remissionClinical improvementDurable responsesMG patientsGravis patientsReceptor autoantibodiesMore hospitalizationsClinical symptomsExamination findingsCell depletionTreatment responsePatientsRituximabB cells
2019
Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients
Takata K, Stathopoulos P, Cao M, Mané-Damas M, Fichtner ML, Benotti ES, Jacobson L, Waters P, Irani SR, Martinez-Martinez P, Beeson D, Losen M, Vincent A, Nowak RJ, O’Connor K. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight 2019, 4: e127167. PMID: 31217355, PMCID: PMC6629167, DOI: 10.1172/jci.insight.127167.Peer-Reviewed Original ResearchConceptsMyasthenia gravisMonoclonal autoantibodiesNeuromuscular junctionMuscle-specific tyrosine kinaseMuSK-MG patientsChronic autoimmune disorderMyasthenia gravis patientsSubset of patientsMouse neuromuscular junctionHuman monoclonal autoantibodiesMuSK autoantibodiesAutoimmune mechanismsGravis patientsMG patientsMost patientsPathogenic autoantibodiesAutoimmune disordersMuscle weaknessNeuromuscular transmissionMuSK phosphorylationAutoantibodiesB cellsAcetylcholine receptorsSynaptic differentiationPatients
2017
Progressive cutaneous Cryptococcosis complicated with meningitis in a myasthenia gravis patient on long-term immunosuppressive therapy – a case report
Huong N, Altibi A, Hoa N, Tuan L, Salman S, Morsy S, Lien N, Truong N, Mai N, Hoa P, Thang N, Trung V. Progressive cutaneous Cryptococcosis complicated with meningitis in a myasthenia gravis patient on long-term immunosuppressive therapy – a case report. BMC Infectious Diseases 2017, 17: 311. PMID: 28446137, PMCID: PMC5406963, DOI: 10.1186/s12879-017-2415-8.Peer-Reviewed Original ResearchConceptsLong-term immunosuppressive therapyImmunosuppressive therapyCutaneous cryptococcosisMyasthenia gravisCutaneous manifestations of cryptococcosisDifferential diagnosis of cutaneous lesionsAssociated with myasthenia gravisDiagnosis of cutaneous lesionsHIV-uninfected individualsManifestation of cryptococcosisChronic immunosuppressive therapyHIV-infected individualsProgressive skin lesionsDevelopment of cryptococcosisMyasthenia gravis patientsCD4 countCryptococcal meningitisDisseminated diseaseCase presentationWeOpportunistic infectionsMonth historyVietnamese male patientMale patientsCutaneous manifestationsDifferential diagnosis
2011
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances In Neurological Disorders 2011, 4: 259-266. PMID: 22010039, PMCID: PMC3187675, DOI: 10.1177/1756285611411503.Peer-Reviewed Original ResearchRefractory myasthenia gravisMyasthenia gravisAcetylcholine receptor antibody titersB cell-directed therapiesReceptor antibody titersSustained clinical improvementMyasthenia gravis patientsPlasma exchange sessionsResponse of patientsCycle 1Immunomodulating therapiesPrednisone doseRituximab therapyClinical improvementConventional immunotherapyGravis patientsProspective trialPlasma exchangeAutoimmune disordersRetrospective studyAntibody titersCertain patientsNeuromuscular transmissionPatientsRituximab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply